DEC-205单抗耦联长循环免疫脂质体的制备及其体外靶向

为使脂质体将所包封的药物或抗原高效地递呈给树突状细胞（dendritic cells,DCs）,诱导产生强烈的T细胞免疫应答或特异性免疫耐受,采用薄膜分散法制备了包裹FITC—dextran的纳米脂质体;用DSPE—PEG（2000）对脂质体膜进行修饰使之具有长循环功能;用异型双功能交联剂SPDP将抗小鼠DEC-205单克隆抗体耦联于脂质体表面使之具有主动靶向DCs的能力。稳定性实验表明脂质体在4℃贮存7d后粒径分布变化较小,FITC—dextran累积泄漏率小于7％;体外结合实验证明耦联抗DEC-205的免疫脂质体（anti—DEC-205 iLPSM）可特异性地识别DCs,并作为良好载体将FITC—dextran带入DCs浆内。成熟树突状细胞（mDC）与未成熟树突状细胞（iDC）均可高效摄取anti—DEC-205iLPSM,iDC摄取能力更强。anti-DEC-205iLPSM有望成为一种新型DC疫苗应用于临床。     

靶向树突状细胞表面分子DEC-205的长循环免疫脂质体稳定性影响因素的数学模型

在多相分散体系的动力稳定性理论基础上,设计了以DEC-205单抗为导向、以脂质体为载体、DCs为靶点的免疫策略,将包裹药物的脂质体特异性地靶向树突状细胞（DCs）．对影响DEC-205的免疫脂质体稳定性的各种因素如粒径分布等进行考察分析,对条件进行优化,构建了经DEC-205单抗靶向DCs的免疫脂质体模型．模型的成功构建为进一步研究抗原靶向DEC-205受体后的体内免疫应答情况提供了工作基础,有望开发一种新型DCs疫苗应用于临床．     

转铁蛋白修饰脂质体的制备及其肝癌靶向性研究

目的：肿瘤的靶向治疗是当前研究的热点,肝肿瘤细胞表面有大量的转铁蛋白受体表达,而正常组织较少,因此本研究制备转铁蛋白（TF）修饰的脂质体（TFLPs）,并对其肝肿瘤靶向性进行研究。方法：采用薄膜分散法制备普通脂质体,考察其形态,粒径,电位。通过体外血清稳定性模拟脂质体进入体内后的稳定性。通过HepG2肿瘤细胞对TFLPs的摄取实验考查脂质体与肝癌细胞的亲和力。构建荷瘤裸鼠模型,考查TFLPs在荷瘤裸鼠体内的分布。结果：所制备的TFLPs平均粒径为108．8±9．5nm,Zeta电位为．1．80±0．73mV。学期稳定性试验结果显示,TFLPs在24h内具有良好的血清稳定性。体外细胞摄取实验表明,HepG2细胞对TFLPs的摄取效率是普通长循环脂质体（LPs）的3．4倍。荷瘤裸鼠肝组织和肿瘤组织切片结果显示,TFLPs比LPs具有更好的肿瘤靶向性。结论：该脂质体制备方法简单,与LPs相比,经转铁蛋白修饰可显著提高肿瘤细胞对脂质体的摄取,TFLPs是一种潜在高效的肝癌靶向给药系统。     

免疫脂质体与人胃癌细胞的相互作用

我们把抗人胃癌细胞M85的单克隆抗体3Hll插入脂质体的脂双层做成免疫脂质体,研究了这些免疫脂质体与M85细胞的相互作用.结果表明,M85细胞对免疫脂质体的吸收与温育时间、温度密切相关.在37℃温育10小时,细胞吸收的免疫脂质体的量是在4℃时的7倍左右.37℃温育5小时,靶向脂质体结合在M85靶细胞上的量是非靶向脂质体的2倍多;与非靶细胞—人皮肤成纤维细胞Fb32的结合量只有与M85靶细胞结合量的1/6.游离单抗3Hll能够抑制靶向脂质体与靶细胞的结合,而专一性与3Hll抗体不同的单抗3G9则不能.NH_4Cl和NaN_3等内吞作用抑制剂使靶细胞吸收免疫脂质体的量分别减少58%和79%.与此同时,NH_4CI还能抑制包入脂质体的ADM,而不能抑制游离ADM的细胞毒作用.因此我们的结论是,3Hll免疫脂质体能够与靶细胞专一地结合,并把所荷载的物质主要经内吞作用输送到细胞内,杀伤靶细胞.用荧光显微镜对与荧光免疫脂质体温育的M85细胞进行的形态观察也支持上述结论.     

曲妥珠单抗修饰的阿霉素免疫脂质体的制备及体外性质研究

目的:制备表面键合曲妥珠单抗(trastuzumab,TMAB)的阿霉素免疫脂质(Doxorubicin-loadedimmunoliposome,DOX-IML),并对其体外性质进行研究。方法:将磷脂酰胆碱、胆固醇、阿霉素、DSPE-MPEG2000以一定比例混合,采用薄膜超声分散法制备阿霉素脂质体,将聚乙二醇衍生物(1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[succinimidyl(polyethylene glycol)-3400]、DSPE-PEG3400-NHS)连接到TMAB;再与阿霉素脂质体连接得到DOX-IML。研究不同浓度的TMAB对DOX-IML入胞能力及细胞毒性的影响;测定免疫脂质体的包封率、载药率、粒径、电荷及稳定性等性质;动态透析法模拟体外释药特性,激光共聚焦观察免疫脂质体对AU565细胞抗体介导的入胞作用;MTT法研究DOX-IML抑制肿瘤细胞的生长。结果:成功制备了表面键合TMAB的阿霉素免疫脂质体,配体载入率分别是53%、75.5%、84%;每毫克DOX-IML中抗体的含量分别是37、83、108μg·mg-1;阿霉素的包封率为76.85%、载药量为8.03%;粒径131.8nm;表面电荷-27mV。抗体含量83μg·mg-1的DOX-IML组的细胞存活率最低,细胞内荧光强度最高,且该免疫脂质体稳定性良好,具有一定缓释作用。DOX-IML具有较强的特异性靶向作用,其入胞能力和细胞毒性均高于阿霉素脂质体。结论:DOX-IML具有较强的特异性靶向作用,其入胞能力和细胞毒性均高于阿霉素脂质体,抗体含量适中时其入胞能力和细胞毒性最强。     

抑制麻疹病毒体外复制的效应性小干扰RNA的鉴定

为了鉴定抑制麻疹病毒体外复制的靶向Rab9GTPase基因效应性小干扰RNA（siRNA）,根据。iRNA设计原则和Rab9GTPase基因的mRNA序列,设计并化学合成8对靶向Rab9GTPase基因的siRNAs和1对阴性对照siRNA,经脂质体法转染Vero—E6细胞株,转染10h后感染麻疹病毒Edmonston株。通过逆转录聚合酶链反应（RT—PCR）检测转染后细胞内Rab9GTPasemRNA水平;通过标准蚀斑试验检测麻疹病毒滴度。同对照组相比,8对靶向Rab9GTPase基因siRNAs中的2对（Rab9-4和Rab9—7）,以时间和剂量依赖性的方式显著地抑制细胞内Rab9GTPasemRNA表达和麻疹病毒的复制（抑制率高达90％以上）,其他的siRNAs对细胞内Rab9GTPasemRNA表达和麻疹病毒的复制的抑制性效应则低于50％。结果表明,Rab9-4和Rab9—7是体外抑制麻疹病毒复制的最有效的siRNAs,这些siRNAs靶序列能被用来深入研究RNA干扰治疗麻疹病毒感染的可能性。     

CCR7在树突状细胞中的功能及对角膜免疫调节的研究进展

树突状细胞（dendritic cells,DCs）是体内已知的功能最强大的专职抗原提呈细胞,对于诱导机体初始免疫应答尤为重要。趋化受体因子7（chemokine receptor 7,CCR7）是一个已知的调节各类免疫细胞向初级、次级淋巴细胞分化,并向外周淋巴器官归巢的趋化因子受体,其具有自我平衡表达能力,在趋化DCs从外周组织迁移至次级淋巴器官中起关键作用。随着研究的深入,除了CCR7最主要的趋化作用外,更多的功能逐渐被了解。目前,DCs和CCR7的相关功能已被应用于诱导角膜移植后的免疫耐受等眼科领域。就CCR7在DCs中的功能及其对角膜免疫调节的影响进行综述,探讨其关键作用及可能的治疗靶点。     

半乳糖配体介导大鼠白介素10基因在大鼠肝脏内的靶向表达

目的 探讨大鼠白介素10（rIL-10）基因是否可通过半乳糖配体介导的脂质体转染法在大鼠肝脏内靶向表达。方法将已构建好的rIL-10基因真核表达质粒与半乳糖配体转染试剂按jetPEI．Gal／DNA（N／P=10）比例混合,通过尾静脉注射转移至大鼠体内。RT—PCR法和ELISA法检测rIL-10基因转移至体内0h、24h、7d和16d后大鼠肝、肾、脾和肺组织及血清中rIL-10的表达情况。结果rIL-10基因转移前大鼠肝、肾、脾和肺组织末扩增出明显rIL-10mRNA表达,转移7d后rIL-10表达主要分布在肝组织。肝组织中rIL-10mRNA表达在基因转移24h和7d时显著升高。血清中的rIL-10浓度在转移后24h和7d浓度分别为（107．92±12．26）pg／ml和（33．2±13．15）pg／ml。结论rIL-10基因通过半乳糖配体介导的脂质体转染法可有效的转移至大鼠体内,并可在肝脏靶向表达一周左右时间。     

KDR靶向RNA干扰对MCF一7细胞凋亡的影响

目的：研究KDR靶向RNA干扰对MCF-7细胞凋亡的影响,探讨其可能的机制。方法：采用阳离子脂质体Lipofecta．mine2000TM作为转染试剂将人KDR基因的siRNA转染人类乳腺细胞株MCF-7,诱RNAi,采用Hoechst33258染色和半定量RT—PCR检测Caspase-3、survivin的mRNA表达及细胞凋亡变化;比色法检测Caspase．3的活性;利用免疫组织化学方法检测survivin的表达,并用图像分析仪分析蛋白表达强度。结果：靶向KDR的siRNA转染MCF-7后,Caspase-3的mRNA表达上调,survivin基因mRNA及蛋白表达水平下调（P〈0．05）。结论：KDRsiRNA通过减少乳腺癌细胞survivin的表达,增加Caspase．3表达来促进肿瘤细胞凋亡,发挥其抗肿瘤作用。     

HPVm16E7刺激树突状细胞SOCS1基因沉默后对宫颈癌小鼠模型免疫效应的影响

摘要 目的：在宫颈癌细胞TC-1的荷瘤小鼠模型中探讨树突状细胞（DCs）的细胞因子信号抑制物1（SOCS1）基因沉默后对宫颈癌细胞免疫效应的影响。方法：构建宫颈癌细胞系TC-1的荷瘤小鼠模型,将含有SOCS1沉默基因的慢病毒载体感染DCs细胞,对荷瘤小鼠进行细胞免疫后监测小鼠体内肿瘤生长、小鼠存活率,并检测小鼠脾细胞对TC-1细胞的体外裂解率以及γ干扰素（IFN-γ）、白细胞介素-12（IL-12）表达等指标。结果：DCs SOCS1基因沉默后可延长小鼠存活期,增强DCs对小鼠体内肿瘤生长的抑制作用,增强小鼠脾细胞对TC-1细胞的体外裂解率(P<0.05),增加小鼠血清IL-12因子表达(P<0.05)和小鼠脾细胞IFN-γ表达(P<0.05),但对小鼠脾内效应细胞的数量没有影响(P>0.05)。结论：小鼠体内实验初步证实,DCs SOCS1基因沉默后可一定程度上增强小鼠体内效应细胞对肿瘤细胞的杀伤效果。     

Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice

Viral vaccine vectors have emerged as an attractive strategy for the development of a human immunodeficiency virus (HIV) vaccine. Recombinant Newcastle disease virus (rNDV) stands out as a vaccine vector since it has a proven safety profile in humans, it is a potent inducer of both alpha interferon (IFN-α) and IFN-β) production, and it is a potent inducer of dendritic cell (DC) maturation. Our group has previously generated an rNDV vector expressing a codon-optimized HIV Gag protein and demonstrated its ability to induce a Gag-specific CD8(+) T cell response in mice. In this report we demonstrate that the Gag-specific immune response can be further enhanced by the targeting of the rNDV-encoded HIV Gag antigen to DCs. Targeting of the HIV Gag antigen was achieved by the addition of a single-chain Fv (scFv) antibody specific for the DC-restricted antigen uptake receptor DEC205 such that the DEC205 scFv-Gag molecule was encoded for expression as a fusion protein. The vaccination of mice with rNDV coding for the DC-targeted Gag antigen induced an enhanced Gag-specific CD8(+) T cell response and enhanced numbers of CD4(+) T cells and CD8(+) T cells in the spleen relative to vaccination with rNDV coding for a nontargeted Gag antigen. Importantly, mice vaccinated with the DEC205-targeted vaccine were better protected from challenge with a recombinant vaccinia virus expressing the HIV Gag protein. Here we demonstrate that the targeting of the HIV Gag antigen to DCs via the DEC205 receptor enhances the ability of an rNDV vector to induce a potent antigen-specific immune response.     

香菇多糖对小鼠骨髓树突状细胞表型和功能的影响

通过研究香菇多糖(Lentinan,LNT)对小鼠骨髓源树突状细胞(bone marrow dendritic cells,BMDCs)功能调节的机制,进一步阐明香菇多糖的免疫活性。本实验将BMDCs分成脂多糖(LPS)阳性对照组、LNT处理组和RPMI1640空白对照组,应用酸性磷酸酶活性检测、流式细胞仪检测技术、吞噬实验、酶联免疫吸附试验检测各组BMDCs表型和功能的各种指标。结果显示,LNT(50μg/mL)处理组BMDCs酸性磷酸酶活性降低;BMDCs吞噬能力比RPMI1640空白对照组明显下降;BMDCs表面MHCⅡ、CD40、CD83、CD80、CD86和DEC205的表达增加;BMDCs白细胞介素12(IL-12)、白细胞介素10(IL-10)和肿瘤坏死因子-α(TNF-α)的表达增加。证明了适宜浓度的LNT可以促进BMDCs表型及功能的成熟。     

DEC205在幽门螺杆菌感染胃上皮细胞中的表达

目的：探讨幽门螺杆菌及其热休克蛋白60（H．pylori—HSP60）感染与胃上皮细胞表面DEC205受体的关系。方法：分别用H．pylori、H．pylori-HSP60及E．coliLPS刺激胃上皮细胞KATOIII,利用免疫荧光染色技术观察KATOIII细胞表面DEC205蛋白的表达变化,再利用RT—PCR技术,观察细胞中DEC205mRNA对上述抗原刺激后的变化。结果：H．pylori、H．pylori—HSP60及E．coliLPS的刺激明显引起细胞表面DEC205蛋白的表达以及细胞内DEC205mRNA的产生。结论：H．pylori感染与胃上皮细胞表面的胞吞受体DEC205有着密切的关系。     

Identification and characterization of novel bone marrow myeloid DEC205+Gr-1+ cell subsets that differentially express chemokine and TLRs

Bone marrow-derived immunomodulatory cytokines impart a critical function in the regulation of innate immune responses and hemopoiesis. However, the source of immunomodulatory cytokines in murine bone marrow and the cellular immune mechanisms that control local cytokine secretion remain poorly defined. Herein, we identified a population of resident murine bone marrow myeloid DEC205(+)CD11c(-)B220(-)Gr1(+)CD8alpha(-)CD11b(+) cells that respond to TLR2, TLR4, TLR7, TLR8, and TLR9 agonists as measured by the secretion of proinflammatory and anti-inflammatory cytokines in vitro. Phenotypic and functional analyses revealed that DEC205(+)CD11b(+)Gr-1(+) bone marrow cells consist of heterogeneous populations of myeloid cells that can be divided into two main cell subsets based on chemokine and TLR gene expression profile. The DEC205(+)CD11b(+)Gr-1(low) cell subset expresses high levels of TLR7 and TLR9 and was the predominant source of IL-6, TNF-alpha, and IL-12 p70 production following stimulation with the TLR7 and TLR9 agonists CpG and R848, respectively. In contrast, the DEC205(+)CD11b(+)Gr-1(high) cell subset did not respond to CpG and R848 stimulation, which correlated with their lack of TLR7 and TLR9 expression. Similarly, a differential chemokine receptor expression profile was observed with higher expression of CCR1 and CXCR2 found in the DEC205(+)CD11(+)Gr-1(high) cell subset. Thus, we identified a previously uncharacterized population of resident bone marrow cells that may be implicated in the regulation of local immune responses in the bone marrow.     

Immunostimulation of dendritic cells by cationic liposomes

A nano-aggregate liposome-polycation-DNA (LPD), composed of a cationic lipid, protamine and plasmid DNA was found to effectively deliver a human papillomavirus (HPV)-E7 epitope antigen to the antigen presenting cells of the immune system, eliciting enhanced anti-tumor immune responses in mouse models of cervical carcinoma. Both the cationic liposome and plasmid DNA were essential for the full immunostimulation activity of LPD. Interestingly, cationic liposomes alone could stimulate the antigen presenting dendritic cells (DC) leading to the expression of co-stimulatory molecules, CD80 and CD86. However, cationic lipids could not stimulate DC for the expression of pro-inflammatory cytokines. Moreover, they were unable to enhance the expression of NF-κB, suggesting that dendritic cells stimulation by cationic lipids is signaled through an NF-κB independent mechanism. DC stimulation was specific to cationic lipids, the zwitterionic and anionic lipids showed little or no activity. The ability of different cationic lipids to stimulate the expression of co-stimulatory molecules on DC varied significantly. In general, the cationic lipids bearing ethyl phosphocholine head groups were better stimulants than their trimethylammonium counterparts. In case of the cationic lipids bearing trimethyl ammonium head groups, the ones bearing unsaturated or shorter saturated hydrophobic chains exhibited enhanced immunostimulatory activity. The LPS-induced TNF-α expression by dendritic cells was inhibited by active cationic lipids but not the inactive ones, suggesting the possible involvement of lipopolysaccharide binding protein (LBP) in cationic lipid mediated DC stimulation. Based on the structure-specific activation of dendritic cells by cationic lipids, a model for the immunostimulation of DC by such lipids is proposed.     

Immunoglobulin immobilized liposomal constructs for transmucosal vaccination through nasal route

The aim of the present investigation was to evaluate the prospective of surface-engineered vesicular carriers for mucosal immunization via the nasal route. IgG antibody was immobilized on the surface of hepatitis B surface antigen (HBsAg) antigen–loaded liposomes. The developed formulations were characterized on the basis of physicochemical parameters, such as morphology, particle size, polydispersity index, entrapment efficiency, and zeta potential. Liposomal formulations were then evaluated for in-process antigen stability and storage stability. In vivo studies were conducted to visualize targeting potential, localization pattern, and immunogenicity. In addition, immune response was compared with alum-HBsAg vaccine injected intramuscularly. The serum anti-HBsAg titer, obtained from the postnasal administration of IgG-coupled liposomes, was significantly higher than plain liposomes. Moreover, IgG-coupled liposomes generated both humoral (i.e., systemic and mucosal) and cellular immune responses upon nasal administration, while the alum-adsorbed antigen displayed neither cellular (cytokine level) nor mucosal (IgA) response. The formulation also displayed enhanced transmucosal transport, improved in vitro stability, and effective immunoadjuvant property. To conclude, IgG antibody-coupled liposomes may serve as novel carriers to augment the secretory immune response of antigen encapsulated in the liposomes, apparently by escalating liposome uptake via M cells, thereby rationalizing their use as a carrier adjuvant for nasal subunit vaccines.     

Liver-derived DEC205+B220+CD19- dendritic cells regulate T cell responses

Leukocytes resident in the liver may play a role in immune responses. We describe a cell population propagated from mouse liver nonparenchymal cells in IL-3 and anti-CD40 mAb that exhibits a distinct surface immunophenotype and function in directing differentiation of naive allogeneic T cells. After culture, such cells are DEC-205(bright)B220+CD11c-CD19-, and negative for T (CD3, CD4, CD8alpha), NK (NK 1.1) cell markers, and myeloid Ags (CD11b, CD13, CD14). These liver-derived DEC205+B220+ CD19- cells have a morphology and migratory capacity similar to dendritic cells. Interestingly, they possess Ig gene rearrangements, but lack Ig molecule expression on the cell surface. They induce low thymidine uptake of allogeneic T cells in MLR due to extensive apoptosis of activated T cells. T cell proliferation is restored by addition of the common caspase inhibitor peptide, benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (zVAD-fmk). T cells stimulated by liver-derived DEC205+B220+D19- cells release both IL-10 and IFN-gamma, small amounts of TGF-beta, and no IL-2 or IL-4, a cytokine profile resembling T regulatory type 1 cells. Expression of IL-10 and IFN-gamma, but not bioactive IL-12 in liver DEC205+B220+CD19- cells was demonstrated by RNase protection assay. In vivo administration of liver DEC205+B220+CD19- cells significantly prolonged the survival of vascularized cardiac allografts in an alloantigen-specific manner.     

Antigen Delivery to DEC205+ Dendritic Cells Induces Immunological Memory and Protective Therapeutic Effects against HPV-Associated Tumors at Different Anatomical Sites

The generation of successful anticancer vaccines relies on the ability to induce efficient and long-lasting immune responses to tumor antigens. In this scenario, dendritic cells (DCs) are essential cellular components in the generation of antitumor immune responses. Thus, delivery of tumor antigens to specific DC populations represents a promising approach to enhance the efficiency of antitumor immunotherapies. In the present study, we employed antibody-antigen conjugates targeting a specific DC C-type lectin receptor. For that purpose, we genetically fused the anti-DEC205 monoclonal antibody to the type 16 human papillomavirus (HPV-16) E7 oncoprotein to create a therapeutic vaccine to treat HPV-associated tumors in syngeneic mouse tumor models. The therapeutic efficacy of the αDEC205-E7 mAb was investigated in three distinct anatomical tumor models (subcutaneous, lingual and intravaginal). The immunization regimen comprised two doses of the αDEC205-E7 mAb coadministered with a DC maturation stimulus (Polyinosinic:polycytidylic acid, poly (I:C)) as an adjuvant. The combined immunotherapy produced robust antitumor effects on both the subcutaneous and orthotopic tumor models, stimulating rapid tumor regression and long-term survival. These outcomes were related to the activation of tumor antigen-specific CD8⁺ T cells in both systemic compartments and lymphoid tissues. The αDEC205-E7 antibody plus poly (I:C) administration induced long-lasting immunity and controlled tumor relapses. Our results highlight that the delivery of HPV tumor antigens to DCs, particularly via the DEC205 surface receptor, is a promising therapeutic approach, providing new opportunities for the development of alternative immunotherapies for patients with HPV-associated tumors at different anatomical sites.